Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe

Enhertu to demonstrate a significant survival benefit vs. chemotherapy

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit

Aurigene reports results of AUR101 in phase II study in US patients

AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients

Mandaviya inaugurates ICMR-NARFBR in Hyderabad

The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.

Synchron raises $75 mn Series C Led by ARCH Venture Partners

Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors

Kerala Ayurveda receives US patent for its herbal formulation

The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders

European Commission approves SPEVIGO for generalized pustular psoriasis flares

EC grants conditional marketing authorization based on the EFFISAYIL trial

Steps taken by Govt. to support diabetes patients

As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years

PM lays foundation stone for National Institute for One Health in Nagpur

The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents